A 32-year-old man with schizophrenia has been on risperidone 6 mg/day for 8 months. He presents to the psychiatry clinic with complaints of difficulty maintaining erections and reduced libido for the past 3 months. His wife reports he has gained 8 kg over the past 6 months. On examination, he appears euthymic with no acute psychotic symptoms. Prolactin level is 85 ng/mL (normal <25 ng/mL). What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient presents with **risperidone-induced hyperprolactinemia** manifesting as sexual dysfunction (erectile dysfunction and reduced libido), weight gain, and laboratory confirmation of elevated prolactin (85 ng/mL). ## Pathophysiology of Antipsychotic-Induced Hyperprolactinemia **Key Point:** Dopamine is the physiologic prolactin-inhibiting factor (PIF). Antipsychotics block D2 receptors in the tuberoinfundibular pathway, removing dopaminergic inhibition and causing prolactin elevation. **High-Yield:** Risk hierarchy for prolactin elevation: 1. Risperidone (highest) — 40–50% of patients 2. Paliperidone (very high) 3. Amisulpride (high) 4. Typical antipsychotics (high) 5. Olanzapine (moderate) 6. Quetiapine (low) 7. Aripiprazole (lowest — dopamine agonist effect) ## Management Strategy | Approach | Rationale | Evidence | |----------|-----------|----------| | **Switch to low-prolactin agent** | Addresses root cause; eliminates need for additional medications | First-line per most guidelines | | Add dopamine agonist (bromocriptine) | Effective but adds medication burden; risk of psychotic relapse | Second-line if switching not possible | | Reduce dose | May compromise antipsychotic efficacy; sexual dysfunction may persist | Not recommended as sole strategy | | Add sildenafil only | Treats symptom, not cause; prolactin remains elevated | Adjunctive only | **Clinical Pearl:** Aripiprazole and quetiapine have minimal prolactin elevation due to their pharmacology (aripiprazole is a partial D2 agonist; quetiapine has weak D2 binding). Switching is the preferred intervention. **Tip:** Always monitor prolactin levels post-switch to confirm normalization (takes 2–4 weeks). ## Why Switching Is Optimal 1. **Addresses pathophysiology** — removes the D2-blocking agent causing hyperprolactinemia 2. **Avoids polypharmacy** — no need for bromocriptine 3. **Prevents complications** — reduces risk of gynecomastia, osteoporosis, and sexual dysfunction 4. **Maintains efficacy** — aripiprazole and quetiapine are effective antipsychotics [cite:Stahl's Essential Psychopharmacology Ch 5]